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Abstract
Background: Human cytomegalovirus (HCMV) can cause poor outcomes in solid organ transplant (SOT) recipients;
moreover, it is associated with cardiovascular diseases (CVD) in the general population. Accordingly, anti-HCMV
immunoglobulin G (IgG) seroepidemiology may be useful in identifying the risk of post-SOT HCMV infection or
disease as well as immunosenescence or CVD. However, HCMV seroprevalence and titre have not been fully
evaluated with regard to age distribution or compared between SOT recipients and healthy individuals in South
Korea.
Methods: We retrospectively retrieved all unduplicated anti-HCMV IgG results of individuals aged > 1 year evaluated
between July 2006 and November 2017 at Severance Hospital in Seoul. The cohort, excluding haematopoietic stem
cell transplant recipients and subjects with equivocal values, included 2184 SOT recipients and 3015 healthy
transplant donors. All IgG results in the SOT recipients were measured during the pre-transplant period.
Results: The overall IgG seroprevalence and titres were significantly higher among SOT recipients than among
healthy donors (98.7% vs. 88.6%, p < 0.001, and 64.7 ± 44.3 vs. 49.8 ± 20.6 arbitrary units/mL, p < 0.001, respectively).
The lowest seropositive rate in the SOT group was observed in recipients aged between 11 and 15 years (70.6%).
The frequency of seropositivity among adults aged ≥41 years increased to ≥90% in SOT recipients and healthy
donors. Age was independently associated with higher HCMV seroprevalence (41–60 years, OR, 76.4, 95% CI, 24.5–
238.9, p < 0.001; ≥ 61 years, OR, 4.4, 95% CI, 1.3–14.9, p < 0.001, compared to ≤40 years). The healthy donor group
had an independently low HCMV seropositive rate (OR, 0.1, 95% CI, 0.1–0.2, p < 0.001).
Conclusions: HCMV seropositivity was the lowest among school-aged children and adolescents. IgG testing
revealed an intermediate serostatus risk of post-transplant HCMV infection and disease for most adult SOT
recipients in South Korea.
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Background
The genomic DNA of human cytomegalovirus (HCMV)
can be incorporated into the host chromosome after pri-
mary acquisition, usually in early life, and be retained in
a latent form throughout life [1–4]. The complicated
mechanisms involved in the latent-to-lytic switch can in-
duce temporary or sustained HCMV replication, leading
to active cytolytic inflammation [1, 3, 4]. In both
immunocompetent and immunocompromised patients,
reactivation of latent HCMV can result in direct tissue
damage that causes end organ disease [1, 5–7]. In
addition, the indirect immunomodulatory effects caused
by the reactivated HCMV may produce detrimental out-
comes, such as increased mortality and graft dysfunction
or failure and rejection, in recipients of solid organ
transplantation (SOT) [8, 9]. Moreover, the persistent
and excessive activation of the HCMV-specific cell-
mediated immune response and the consequent immune
exhaustion or accelerated immunosenescence in the non-
immunocompromised population could predispose these
individuals to chronic inflammatory diseases, such as
cardiovascular diseases (CVDs), as well as aging [10–13].
The profound clinical influence of HCMV on personal
and public health makes it reasonable to acquire detailed
information regarding the number of individuals that
have asymptomatic HCMV in a certain region [14]. Sur-
veillance for HCMV seroprevalence, which is assessed
using an anti-HCMV immunoglobulin G (IgG) test, may
be epidemiologically important as a means of predicting
various related chronic diseases, particularly in older
subjects, as global societies age [11, 12, 15]. Additionally,
the pre-transplant HCMV serostatus in donors and re-
cipients is an important factor predicting post-transplant
HCMV infection and disease; moreover, it provides in-
formation that would be useful in developing individu-
ally tailored anti-HCMV preventive strategies for SOT
recipients [1, 3, 9, 16, 17].
The anti-HCMV IgG positive rates vary widely by era,
geographic distribution, age group, and population char-
acteristics [18, 19]. In 2019, Zuhair et al. estimated the
mean HCMV seroprevalence in the global general popu-
lation to be 83% (95% uncertainty interval, 78–88%),
ranging from 90% (85–94%) in the Eastern Mediterra-
nean region to 66% (56–74%) in Europe, among the six
regions demarcated by the World Health Organization
(WHO) [14]. The national burden of HCMV also varies
between 18% in Canada and 100% in Egypt, Iran,
Thailand, and Turkey [14]. However, no report, to
our knowledge, has evaluated HCMV seroepidemiol-
ogy across all ages of a general population, among
women of reproductive age, or among SOT recipients
in South Korea, which has experienced rapid socio-
economic development and advances in public health
in recent years [14, 20].
Therefore, this study aimed to evaluate the recent
HCMV seroprevalence and anti-HCMV IgG titres
among SOT recipients, particularly according to age dis-
tribution, in Seoul, South Korea.
Methods
Study design and population
For the retrospective cohort study, we retrieved all un-
duplicated anti-HCMV IgG results and IgG titres for
tests performed between July 2006 and November 2017
from the electronic medical records of Severance Hos-
pital, a university-affiliated tertiary care centre in Seoul,
South Korea. Infants (n = 488) were excluded, because
they could possess maternal anti-HCMV IgG for a year
after birth [21]. After the further deletion of 34 equivocal
results, we stratified the total cohort into two groups of
2184 SOT recipients and 3015 healthy transplant donors
who underwent this screening for organ donation, irre-
spective of the implementation of donation surgery. The
SOT recipients group included all recipients who re-
ceived transplants from living or deceased donors. Our
cohort did not include SOT recipients had received
haematopoietic stem cell transplantation (HSCT) before
and after SOT or re-transplantation or multiple-organ
transplantation or human immunodeficiency virus-
infected individuals. For all SOT recipients, anti-HCMV
IgG values were evaluated during the pre-transplant
period within 3 months of SOT. The ages at the time of
testing, anti-HCMV IgG titres, and transplant organs
were also recorded. Patient ages were grouped in 5-year
intervals up to 40 years of age and, then, in 20-year in-
tervals. The study was approved by the institution review
board in Gangnam Severance Hospital, which waived
the requirement for informed consent because of retro-
spective data collection without personally identifiable
information (IRB approval No: 3–2018-0139).
Measurement of anti-human cytomegalovirus IgG
antibody
Serum samples were automatically subjected to quantita-
tive anti-HCMV IgG testing using an enzyme-linked
fluorescent immunoassay (VIDAS®, bioMérieux Cop.,
Marcy-l’Etoile, Lyon, France). Antigens from the HCMV
AD169 laboratory strain were used as the positive con-
trol. The antibody titre is expressed in arbitrary units
(aU)/mL. Qualitatively, the results were reported as posi-
tive, equivocal, and negative if the titres were ≥ 6, 4 to <
6, and < 4 aU/mL, respectively. The results of anti-
HCMV IgG tests in the analyses were categorised as
positive or negative.
Statistical analyses
We used the independent two-sample t-test and the chi-
square test or Fisher’s exact test, respectively, to examine
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differences in continuous and nominal variables between
SOT recipients and healthy transplant donors. The post-
hoc analyses in the nominal variables were performed by
adjusted standardised residuals to control for type I
error inflation (adjusted p value). An analysis of variance
(ANOVA) with the Bonferroni post-hoc test was used
for multiple comparisons of IgG titres between trans-
plant organs. Multivariate logistic regression analyses
were performed to identify the independent effects of
age groups and sex on HCMV seropositivity. Data are
expressed as numbers (percentages) or means ± stand-
ard deviations or odds ratio (OR) (95% confidence inter-
vals [CI]). SAS version 9.3 (SAS Institute Inc., Cary, NC,
USA) was used for the statistical analyses. A two-tailed
p-value ≤0.05 was considered statistically significant.
Results
HCMV IgG results from SOT recipients and healthy
transplant donors
The overall anti-HCMV IgG positivity rate was 92.8% in
the total of 5199 subjects. The HCMV seropositivity in
males was not significantly different from that in females
among SOT recipients (99.8% [n = 1354] vs. 98.4% [n =
830], p = 0.564). However, among healthy transplant
donors, males had a significantly lower HCMV seroposi-
tive rate (84.1% [n = 1681] vs. 86.8% [n = 1334], p =
0.039). The frequency of anti-HCMV IgG positivity in
all ages was significantly higher among SOT recipients
than among healthy transplant donors (98.7% vs. 88.6%,
p < 0.001) (Table 1).
HCMV seroprevalence according to age groups
There were few subjects aged ≤15 years in the SOT re-
cipients group (44/2184, 2.0%) and none in the group of
3015 healthy transplant donors. The proportion of anti-
HCMV IgG positive results was extremely high among
SOT recipients aged ≥31 years and among healthy trans-
plant donors aged ≥61 years. In contrast, HCMV sero-
positive rates were the lowest among those between 11
and 15 years of age in the SOT recipients group (70.6%)
and those between 16 and 20 years of age among the
healthy transplant donors (54.8%). The HCMV seroposi-
tivity in the healthy donors continuously increased with
age from 54.8% in those aged between 16 and 20 years
to 99.5% in those ≥61 years of age (Table 1).
SOT recipients had significantly higher rates of sero-
positivity, compared to healthy transplant donors, among
those between 16 to 20 (93.2% vs. 54.8%, p < 0.001), 21 to
Table 1 HCMV IgG seroprevalence in solid organ transplant recipients and healthy transplant donors by age distribution
Age (years) Anti-HCMV IgG SOT recipients (n = 2184) Healthy transplant donors (n = 3015) p-value
1–5 Positive 12 (80.0) 0 (0) N/A
Negative 3 (20.0) 0 (0)
6–10 Positive 9 (75.0) 0 (0) N/A
Negative 3 (25.0) 0 (0)
11–15 Positive 12 (70.6) 0 (0) N/A
Negative 5 (29.4) 0 (0)
16–20 Positive 41 (93.2) 46 (54.8) <0.001
Negative 3 (6.8) 38 (45.2)
21–25 Positive 54 (90.0) 162 (63.3) <0.001
Negative 6 (10.0) 94 (36.7)
26–30 Positive 114 (96.6) 262 (78.9) <0.001
Negative 4 (3.4) 70 (21.1)
31–35 Positive 133 (99.3) 307 (86.5) <0.001
Negative 1 (0.7) 48 (13.5)
36–40 Positive 215 (99.1) 229 (89.8) <0.001
Negative 2 (0.9) 26 (10.2)
41–60 Positive 1287 (99.8) 1088 (94.3) <0.001
Negative 2 (0.2) 66 (5.7)
≥ 61 Positive 278 (100) 576 (99.5) 0.555
Negative 0 (0) 3 (0.5)
Total Positive 2155 (98.7) 2670 (88.6) <0.001
Negative 29 (1.3) 345 (11.4)
Data are expressed as number (percent). Abbreviations: HCMV Human cytomegalovirus, IgG immunoglobulin G, N/A not available, SOT solid organ transplantation
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25 (90.0% vs. 63.3% p < 0.001), 26 to 30 (96.6% vs. 78.9%,
p < 0.001), 31 to 35 (99.3% vs. 86.5%, p < 0.001), 36 to 40
(99.1% vs. 89.8%, p < 0.001) and 41 to 60 years of age
(99.8% vs. 94.3%, p < 0.001). The very low HCMV sero-
positive rates in both SOT recipients (0%) and healthy
transplant donors (0.5%) among those aged ≥61 years were
not significantly different (p = 0.555) (Table 1).
Anti-HCMV IgG titres in SOT recipients and healthy
transplant donors
The overall HCMV IgG titre in subjects showing HCMV
seropositivity was significantly higher among SOT recip-
ients (n = 2155) than among healthy transplant donors
(n = 2670; 64.7 ± 44.3 vs. 49.8 ± 20.6 aU/mL; p < 0.001).
In an analysis according to age distribution, SOT recipi-
ents had significantly higher HCMV IgG titres at all ana-
lysable ages than the healthy transplant donors
(Table 2). ANOVA testing revealed that age subgroups
had significantly different HCMV IgG titres in both SOT
recipients and healthy donors (overall p < 0.001).
HCMV seroprevalence and titres according to transplant
organs
The kidney (n = 1436, 65.8%) was most common trans-
plant organ in this cohort. Liver transplant (LT, n = 579)
and lung transplant (LTx, n = 69) recipients had signifi-
cantly higher mean ages, compared to kidney transplant
(KT) and heart transplant (HT) (n = 100) recipients (p <
0.001). In all age groups, overall anti-HCMV IgG titres
among LT (80.1 ± 54.5 aU/mL) and LTx (84.3 ± 68.3 aU/
mL) recipients were significantly higher than those among
KT (59.4 ± 36.1 aU/mL) and HT (58.1 ± 46.9 aU/mL) re-
cipients (p < 0.001). In addition, seropositive rates in all
age groups were significantly higher in LT (99.7%) and
LTx (100%) recipients than in KT (98.3%) and HT (97.0%)
recipients (p = 0.024). However, the HCMV IgG positive
rates and titres were similar among the four-transplant or-
gans in SOT recipients aged ≤40 years (Table 3)
Regression analyses for the effect of age and sex on
HCMV seropositivity
Older age (reference ≤40 years; 41–60 years: OR, 76.42,
95% CI, 24.45–238.85, p < 0.001 and ≥ 61 years: OR, 4.44,
95% CI, 1.32–14.91, p < 0.001) was an independent factor
associated with a higher HCMV IgG positive rate. Healthy
subjects were independently associated with a lower
HCMV seropositive rate (OR: 0.12, 95% CI: 0.08–0.17,
p < 0.001; Table 4).
Discussion
This study reports a very high HCMV seroprevalence in
Seoul, South Korea, a developed country with a high so-
cioeconomic status and well-organised public health sys-
tem [20, 22]. As a result, our data may suggest high
proportions of both seropositive donors and recipients
(D+/R+), which is considered an usual intermediate risk
for post-transplant HCMV infection and/or disease via
the reactivation of a latent virus [9, 16, 23]. Our overall
HCMV IgG seropositive rate is higher than the upper
seroprevalence value (88%) of the 95% uncertainty inter-
val in the worldwide general population, based on a re-
cent meta-regression-based estimation [14]. Seronegative
individuals were extremely rare among those aged ≥31
years in the SOT recipients. In addition, HCMV sero-
positive rates and titres were generally proportional to
age, except for teenagers. As HCMV may be horizontally
transmitted by intimate contact, mainly by hand contact,
the lowest seroprevalence observed in subjects between
11 to 15 years of age could be attributed to primary ac-
quisition of HCMV at adolescence owing to improved
hygiene [24, 25].
These analyses also revealed high HCMV IgG titres in
the elderly population among SOT recipients and healthy
subjects. A high HCMV IgG titre and persistent immune
reactivation caused by an inflation in the population of
long-lived, non-classical HCMV-specific effector memory
CD8+ T lymphocytes have been associated with chronic




Anti-HCMV IgG titre (aU/mL) p-
valueSOT recipients (n = 2155) Healthy transplant donors (n = 2670)
16–20 56.9 ± 35.6 37.6 ± 12.9 <0.001
21–25 60.1 ± 43.9 40.6 ± 26.8 <0.001
26–30 55.0 ± 38.8 42.9 ± 30.8 <0.001
31–35 54.6 ± 27.8 45.3 ± 27.6 <0.001
36–40 64.7 ± 37.1 48.6 ± 29.5 <0.001
41–60 67.8 ± 45.3 52.1 ± 13.4 <0.001
≥ 61 70.4 ± 52.5 55.4 ± 30.1 <0.001
Total 64.7 ± 44.3 49.8 ± 20.6 <0.001
Data are expressed as mean ± standard deviation
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inflammatory diseases, including atherosclerosis, stroke,
and coronary artery disease [3, 4, 11, 26–28]. Therefore,
the findings of high seropositivity and IgG titres in elderly
individuals might suggest the need for further evaluation
to prevent HCMV reactivation in a specific population,
regardless of their immunocompromised status, as this ap-
proach could reduce the morbidity and mortality associ-
ated with inflammatory vascular diseases.
Despite the international distribution of HCMV, sero-
positivity rates around the world vary widely from 18 to
100%, according to geographical location, ethnicity, and
specific subpopulation features [14, 29–32]. In a recent
study by Li et al., stratification of serological profiles by
age group revealed a very high IgG positive rate (97%)
even among young individuals (0–14 years), in contrast
to our data [17]. A study conducted in the Netherlands,
in 2006 to 2007, reported that non-western individuals
(76.7%) had a considerably higher seroprevalence than
native Dutch and western individuals (41.5%) [31]. In
general, the very high HCMV seroprevalence observed
in South Korea is similar to that reported in the WHO
Eastern Mediterranean region, rather than in the
European region or the Americas [14, 29, 31, 32]. The
different breastfeeding rates and HCMV IgM or IgG
seropositive rates of women of reproductive age could
contribute to the varied seroprevalence of HCMV be-
tween countries or regions, because mother-to-infant
vertical transmission may have a major impact on global
epidemiology of HCMV [14, 33, 34].
In a SOT setting reported in Hungary, living organ
donors were found to have an HCMV seroprevalence of
85% [35]. However, a detailed analysis of the pre-
transplant HCMV IgG seropositivity rates and titres
among SOT recipients according to age groups or trans-
plant organs as well as in contrast to healthy subjects
was not fully reported. In our study, SOT recipients had
higher HCMV IgG seropositive rates and titres relative
to healthy transplant donors. In addition, the healthy
individuals were independently associated with signifi-
cantly lower HCMV IgG seroprevalence in a logistic re-
gression model. Patients who need SOT have higher
HCMV seroprevalence and, therefore, exhibit a higher
risk for post-transplant complications associated with
HCMV than patients who do not need SOT. Therefore,
pre-transplant anti-HCMV IgG assessments are clinic-
ally significant in predicting the development of post-
transplant HCMV infection and/or disease [9, 16]. In
addition, the HCMV serostatus can be clinically use-
ful to stratify the risk groups for post-transplant
HCMV reactivation and guide precise HCMV pre-
ventive strategies [9, 16].
It would be informative to reveal that patients who re-
ceived SOT in the end stage organ disease state have
higher HCMV IgG seropositive rates and titres
Table 3 HCMV seropositive rates and anti-HCMV IgG titre by transplant organs in solid organ transplant recipients
Age (years) Kidney Liver Lung Heart p-value
(n = 1436) (n = 579) (n = 69) (n = 100)
≤ 40
Seropositive 478 (95.2) 57 (98.3) 15 (100) 34 (94.4) 0.716
Titre (aU/mL) 57.7 ± 36.6 65.3 ± 42.6 69.5 ± 44.4 51.1 ± 27.0 0.184
41–60
Seropositive 801 (100) 400 (99.8) 33 (100) 47 (97.9) 0.073
Titre (aU/mL) 60.7 ± 34.6*† 81.3 ± 55.5* 88.5 ± 72.3† 66.4 ± 60.7 0.001
≥ 61
Seropositive 133 (100) 120 (100) 21 (100) 16 (100) ―
Titre (aU/mL) 59.9 ± 44.2* 82.9 ± 56.3* 90.3 ± 80.5 48.8 ± 27.4 0.001
Total
Age, year 44.9 ± 12.4*† 52.3 ± 12.0*‡ 50.2 ± 13.0†§ 44.3 ± 17.3‡§ <0.001
Seropositive 1412 (98.3) 577 (99.7)a 69 (100.0)a 97 (97.0) 0.024
Titre (aU/mL) 59.4 ± 36.1*† 80.1 ± 54.5*‡ 84.3 ± 68.3†§ 58.1 ± 46.9‡§ <0.001
Data are expressed as number (percent) or mean ± standard deviation. *†‡§p-value <0.05 between two groups in post-hoc tests by Bonferroni correction after
ANOVA. aadjusted p < 0.05 between two groups using post-hoc analyses based on adjusted standardised residuals. Abbreviation: aU, arbitrary unit
Table 4 Multivariate logistic regression analyses to evaluate the
factors associated with HCMV IgG seropositivity
Variables OR 95% CI p-value
Age, years
≤ 40 Ref. Ref. Ref.
41–60 76.42 24.45–238.85 <0.001
≥ 61 4.44 1.32–14.91 0.016
Sex, male 1.33 0.98–1.64 0.078
Healthy transplant donor 0.12 0.08–0.17 <0.001
Abbreviations: CI confidence interval, OR odds ratio, Ref reference
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compared to heathy individuals. This finding might be
associated with asymptomatic intermittent HCMV
replication and immune boosting against HCMV in
chronic end stage medical diseases as well as poly-
clonal immune activation through pro-inflammatory
cytokine release upon fulminant acute organ failure
leading to SOT [36–39].
This retrospective study has several limitations. We
were unable to perform further subgroup analyses
according to various underlying morbidities and other
immunosuppressive conditions, such as HSCT or
haematologic malignancies with severe prolonged neu-
tropenia. In addition, the study design did not allow the
serial testing of anti-HCMV IgG titres in SOT recipients
at the post-transplant period and subsequent evaluation
of the dynamic change of HCMV IgG titres with recov-
ery of transplanted organ function. Moreover, HCMV
seroprevalence may differ according to study population,
city, and region.
Despite these limitations, this study is the first, to our
knowledge, to report a difference in the qualitative and
quantitative anti-HCMV IgG findings between SOT re-
cipients and healthy individuals according to serial age
groups as well as transplanted organs in SOT recipients.
Conclusion
The overall HCMV seropositive rate in South Korea was
as high as 90% among both SOT recipients and healthy
individuals. Furthermore, the SOT recipients had higher
HCMV seropositive rates and IgG titres than the healthy
donors. Increased age was an independent factor for
high HCMV seropositivity. A large-scale multicentre or
regional serosurveillance in the general population as
well as among immunocompromised patients who
harbour high risks of HCMV infection and life-
threatening end-organ diseases could be helpful.
Abbreviations
aU: Arbitrary unit; CVD: Cardiovascular disease; HCMV: Human
cytomegalovirus; HSCT: Haematopoietic stem cell transplantation; HT: Heart
transplantation; Ig: Immunoglobulin; KT: Kidney transplantation; LT: Liver
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